Results 131 to 140 of about 296,469 (371)

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

BMC Infectious Diseases, 2015
BackgroundThe goal of chronic hepatitis C treatment is to remove the virus to avoid progression of HCV-related disease. Sustained virologic response (SVR) is the most widely used efficacy endpoint in clinical studies of hepatitis C, and represents the ...
J. Smith-Palmer, K. Cerri, W. Valentine
semanticscholar   +1 more source

Mixed cryoglobulinemia decelerates hepatocellular carcinoma development in hepatitis C patients with SVR by downregulating regulatory B cells: a 12-year prospective cohort study

OncoImmunology
How mixed cryoglobulinemia (MC) affects cancer risk in chronic hepatitis C patients with sustained virologic response (SVR) remains unclear. In a 12-year prospective study, post-SVR MC was assessed every 3‒6 months. Among the 891 SVR patients, 265 (29.7%)
Ming-Ling Chang, Jur-Shan Cheng, Wei-Ting Chen, Yi-Jyun Shen, Chia-Jung Kuo, Rong-Nan Chien   +5 more
doaj   +1 more source

Longitudinal liver stiffness assessment in patient with chronic hepatitis C undergoing antiviral therapy. [PDF]

, 2015
BACKGROUND/AIMS:Liver stiffness (LS) measurement by means of transient elastography (TE) is accurate to predict fibrosis stage. The effect of antiviral treatment and virologic response on LS was assessed and compared with untreated patients with chronic ...
Bonowicki, Jean Pierre, Bourlière, Marc, Brunetto, Maurizia, Capron, Dominique, Combis, Jean Marc, Dao, Thong, Forns, Xavier, Foucher, Juliette, Lucidarme, Damien, Lédinghen, Victor de, Martínez, Stella M., Maynard-Met, Marianne, Merrouch, Wasil, Métivier, Sophie   +13 more
core   +2 more sources

Virologic response at week 8 of combined treatment as a predictor of sustained virologic response in non rapid virologic response, chronic HCV genotype 4 infected patients

Egyptian Journal of Medical Human Genetics, 2012
Optimization of interferon-based treatment regimens remains an important goal as pegylated interferon is likely to remain the backbone of chronic HCV treatment in the foreseeable future. The objective of the current study was to evaluate virological response at week 8 of combined treatment as a predictor of sustained virologic response (SVR) in non ...
Monis, Ali, Ali Monis, Ahmed, Al Swaff, Reham   +2 more
openaire   +2 more sources

Boceprevir for untreated chronic HCV genotype 1 infection.

, 2011
International audienceBACKGROUND: Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV).
Albrecht, Janice K, Bacon, Bruce, Boparai, Navdeep, Brass, Clifford A, Bronowicki, Jean-Pierre, Bruno, Sofie, DiNubile, Mark J, Goodman, Zachery, Jacobson, Isaac, Manns, Michael, McCone, Julie, Poordad, Fred, Reddy, K Rajender, Sniukiene, Vilma, SPRINT2-Investigators, the, Sulkowski, Michael, Van Vlierberghe, Hans   +16 more
core   +4 more sources

Durability of Sustained Virologic Response in Chronic Hepatitis C: Analysis of Factors Related to Relapse after Sustained Virologic Response with Peginterferon Plus Ribavirin Combination Therapy

The Korean Journal of Gastroenterology, 2011
Pegylated interferon plus ribavirin combination therapy has been the standard of therapy for patients with chronic hepatitis C. Although previous studies have reported long term durability after the sustained virologic response (SVR) with standard therapy for chronic hepatitis C, it is still unclear in Korea.
Jang Eun, Lee, Na Ri, Yoon, Jin Dong, Kim, Myeong Jun, Song, Jung Hyun, Kwon, Si Hyun, Bae, Jong Young, Choi, Sung Won, Jeong, Seung Kew, Yoon   +8 more
openaire   +2 more sources

Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa [PDF]

, 2012
There is little data on responses to combination antiretroviral therapy (cART) among HIV-infected children in the West African region. We describe treatment outcomes among HIV-1 and HIV-2 infected children initiating cART in a research clinic in The ...
Assan Jaye, Francis Oko, Ingrid Peterson, John Townend, Kevin Peterson, Toyin Togun, Uduak Okomo   +6 more
core   +3 more sources

Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs) [PDF]

, 2023
Waleed Attia Hassan, Sherif Kamel, Ibrahim Abdel Naby Mahmoud, Nahed A. Makhlouf, Mahmoud Moubark, Sahar M. Hassany   +5 more
openalex   +1 more source

Th17 cells favor migration and invasiveness of cervical cancer cells under hypoxia in an IGF2BP2‐dependent manner

International Journal of Cancer, EarlyView.
What's New? Hypoxic regions and inflammatory Th17 cells in the tumor environment are both associated with poor prognosis in cervical cancer. However, synergistic mechanisms between hypoxia and Th17 cells remain elusive. This study demonstrated Th17–hypoxia‐driven mechanisms underlying cervical cancer progression.
Selina Gies, Maike Pohlers, Tanja Tänzer, Emmanuel Ampofo, Matthias W. Laschke, Moritz Schäfer, Yoo‐Jin Kim, Rainer Maria Bohle, Erich‐Franz Solomayer, Konrad Wagner, Martin Empting, Alexandra K. Kiemer, Barbara Walch‐Rückheim   +12 more
wiley   +1 more source

Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C

PLoS ONE, 2015
Introduction Hepatitis C virus (HCV) infection is one of the principle causes of chronic liver disease. Successful treatment significantly decreases the risk of hepatic morbidity and mortality.
P. McEwan, T. Ward, H. Bennett, A. Kalsekar, S. Webster, M. Brenner, Yong Yuan   +6 more
semanticscholar   +1 more source